Prospective Randomized Trial of the Safety and Efficacy of Pioglitazone In Patients With ST Elevation Myocardial Infarction Treated by Primary Stent Implantation
Heart Center of Shonankamakura General Hospital, Kamakura, Japan
T. Shiono, S. Saito, Y. Miyashita, S. Takahashi, H. Domae, Y. Taketani, J. Matsumi, Y. Minami, S. Mizuno, K. Sugitatsu, H. Kaneda
Background: Recent studies have shown that the pioglitazone reduced neointimal hyperplasia after coronary stenting. In this randomized trial, we will examine safety and efficacy of pioglitazone in patients with ST elevation myocardial infarction (STEMI) treated by primary bare metal stent implantation.
Methods: Diabetic or non-diabetic patients with STEMI (<12 hrs from onset) were included between October 2005 and July 2007. Patients were randomized into the pioglitazone (15mg, up to 30mg) or control groups. Primary safety end point was major adverse cardiac events (MACE): composite of all-cause mortality, re-infarction, target lesion revascularization, or heart failure necessitating hospitalization.
Results:
Conclusion: Pioglitazone cannot show the significant difference against angiographic restenosis and MACE in patients with STEMI within 6 months.
summitMD.com
